JP2006525995A - サイトカイン発現細胞ワクチンの組み合わせ - Google Patents

サイトカイン発現細胞ワクチンの組み合わせ Download PDF

Info

Publication number
JP2006525995A
JP2006525995A JP2006507483A JP2006507483A JP2006525995A JP 2006525995 A JP2006525995 A JP 2006525995A JP 2006507483 A JP2006507483 A JP 2006507483A JP 2006507483 A JP2006507483 A JP 2006507483A JP 2006525995 A JP2006525995 A JP 2006525995A
Authority
JP
Japan
Prior art keywords
cells
cytokine
tumor
cell
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006507483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525995A5 (https=
Inventor
ヨース，カリン
クレソン，ジェニファー
リー，ベティ
プレル，ロドニー
アウン，サンドラ
モスカレンコ，マリナ
デュ，トーマス
Original Assignee
セル ジェネシス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セル ジェネシス インコーポレイテッド filed Critical セル ジェネシス インコーポレイテッド
Publication of JP2006525995A publication Critical patent/JP2006525995A/ja
Publication of JP2006525995A5 publication Critical patent/JP2006525995A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2006507483A 2003-04-02 2004-03-24 サイトカイン発現細胞ワクチンの組み合わせ Withdrawn JP2006525995A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/404,662 US20040197312A1 (en) 2003-04-02 2003-04-02 Cytokine-expressing cellular vaccine combinations
PCT/US2004/008846 WO2004093831A2 (en) 2003-04-02 2004-03-24 Cytokine-expressing cellular vaccine combinations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011175553A Division JP5607000B2 (ja) 2003-04-02 2011-08-11 サイトカイン発現細胞ワクチンの組み合わせ

Publications (2)

Publication Number Publication Date
JP2006525995A true JP2006525995A (ja) 2006-11-16
JP2006525995A5 JP2006525995A5 (https=) 2007-05-24

Family

ID=33096962

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006507483A Withdrawn JP2006525995A (ja) 2003-04-02 2004-03-24 サイトカイン発現細胞ワクチンの組み合わせ
JP2011175553A Expired - Fee Related JP5607000B2 (ja) 2003-04-02 2011-08-11 サイトカイン発現細胞ワクチンの組み合わせ
JP2014084319A Pending JP2014169299A (ja) 2003-04-02 2014-04-16 サイトカイン発現細胞ワクチンの組み合わせ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011175553A Expired - Fee Related JP5607000B2 (ja) 2003-04-02 2011-08-11 サイトカイン発現細胞ワクチンの組み合わせ
JP2014084319A Pending JP2014169299A (ja) 2003-04-02 2014-04-16 サイトカイン発現細胞ワクチンの組み合わせ

Country Status (5)

Country Link
US (3) US20040197312A1 (https=)
EP (3) EP2574346A1 (https=)
JP (3) JP2006525995A (https=)
CA (1) CA2519563A1 (https=)
WO (1) WO2004093831A2 (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503039A (ja) * 2007-11-07 2011-01-27 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ 癌治療用医薬組成物
JP2013525450A (ja) * 2010-04-27 2013-06-20 ザ・ジョンズ・ホプキンス・ユニバーシティ 新生物（腫瘍）を治療するための免疫原性組成物及び方法。
JP2014527983A (ja) * 2011-09-19 2014-10-23 ザ ジョンズ ホプキンス ユニバーシティー 癌免疫療法
JP2015518901A (ja) * 2012-06-08 2015-07-06 アデュロ バイオテック 癌免疫療法のための組成物および方法
JP2015523412A (ja) * 2012-07-30 2015-08-13 ワウ ヒン イェウング，アレックス 腫瘍細胞、ＧＭ‐ＣＳＦのトランスジェニック発現を伴う腫瘍溶解性ウイルスベクター、および免疫チェックポイントモジュレーターなどの成分の少なくとも２種または全３種の同時投与により作られる生のｉｎｖｉｖｏ腫瘍特異的がんワクチンシステム
JP2019135251A (ja) * 2015-05-20 2019-08-15 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
US11596660B2 (en) 2017-04-14 2023-03-07 Cg Oncology, Inc. Methods of treating bladder cancer
US11759509B2 (en) 2013-03-29 2023-09-19 Sumitomo Pharma Co., Ltd. WT1 antigen peptide conjugate vaccine
US12383608B2 (en) 2016-11-30 2025-08-12 Sumitomo Pharma Co., Ltd. WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides
JP2025531267A (ja) * 2022-09-16 2025-09-19 コリア ニュークリア エンジニアリング カンパニー リミテッド アブスコパル効果を有する、がんの予防または治療用組成物およびこれを用いたがんの予防または治療方法

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7297204B2 (en) 2004-02-18 2007-11-20 Meadwestvaco Corporation Water-in-oil bituminous dispersions and methods for producing paving compositions from the same
JP2006265155A (ja) * 2005-03-23 2006-10-05 Link Genomics Kk 癌の免疫療法
EP1874342B1 (en) * 2005-04-26 2018-06-06 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
KR101492643B1 (ko) 2005-12-02 2015-02-12 이칸 스쿨 오브 메디슨 엣 마운트 시나이 비-천연 표면 단백질을 제시하는 키메라 바이러스 및 그의용도
EP2010207A4 (en) * 2006-03-22 2009-12-02 Imp Innovations Ltd COMPOSITIONS AND METHODS RELATING TO THE MODULATION OF COMPONENTS OF THE IMMUNE SYSTEM
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
US7919079B2 (en) * 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
WO2007130493A2 (en) * 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US20080045589A1 (en) * 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
DK2073837T3 (da) * 2006-10-06 2014-09-29 Bavarian Nordic Inc Rekombinant modificeret vaccinia-ankara-virus, der koder for et her-2-antigen, i kombination med en taxan til anvendelse til behandling af cancer
US20080181874A1 (en) * 2007-01-29 2008-07-31 Alexander Kharazi Cell composition and method for treating cancer
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
WO2009032256A2 (en) * 2007-08-30 2009-03-12 Cell Genesys, Inc. Apc activators in combination with a cytokine-secreting cell and methods of use thereof
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
ES2550179T3 (es) 2009-02-05 2015-11-05 Icahn School Of Medicine At Mount Sinai Virus quiméricos de la enfermedad de Newcastle y usos de los mismos
US9572894B2 (en) * 2010-10-18 2017-02-21 The University Of Iowa Research Foundation Biodegradable particulate formulations
BR112014005091A2 (pt) 2011-09-05 2017-06-13 Beijing Hanmi Pharmaceutical Co Ltd composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa
EA038981B1 (ru) 2013-03-14 2021-11-17 Икан Скул Оф Медсин Эт Маунт Синай Вирусы болезни ньюкасла и их применение
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
EP3082853A2 (en) * 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
WO2015127501A1 (en) 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
WO2015131176A1 (en) * 2014-02-28 2015-09-03 Podack Eckhard R Compositions, methods, and kits for treatment of cancer
CN107073079A (zh) * 2014-09-08 2017-08-18 达纳－法伯癌症研究所公司 包括给予PPAR‑γ激动剂的治疗癌症的方法
KR20190026061A (ko) * 2014-10-15 2019-03-12 스미또모 가가꾸 가부시끼가이샤 리튬 이차 전지용 정극 활물질, 리튬 이차 전지용 정극 및 리튬 이차 전지
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
BR112017016681A2 (pt) * 2015-02-06 2018-04-10 Heat Biologics Inc vetor de coexpressão de vacina e moléculas coestimulatórias
MX383691B (es) 2015-03-06 2025-03-14 Beyondspring Pharmaceuticals Inc Método de tratamiento de cáncer asociado con una mutación de ras.
AU2016240411A1 (en) * 2015-04-02 2017-10-12 Cancure Limited Agents and compositions for eliciting an immune response
CA2984794A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
TW202523682A (zh) 2015-05-20 2025-06-16 美商博德研究所有限公司 共有之gata3相關之腫瘤特異性新抗原
TN2019000101A1 (en) 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
JP2018519327A (ja) * 2015-06-29 2018-07-19 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． 治療用組成物、組合せ物および使用の方法
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods for using them
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
WO2017139231A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
RU2760348C2 (ru) 2016-06-06 2021-11-24 Бейондспринг Фармасьютикалс, Инк. Способ уменьшения нейтропении
WO2017223090A1 (en) * 2016-06-21 2017-12-28 The Trustees Of Columbia University In The City Of New York Whole-cell based vaccine against zika virus
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
KR20260039788A (ko) 2017-10-10 2026-03-20 시애틀 프로젝트 코포레이션 핫스팟을 이용한 신생항원 동정
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
US12527821B2 (en) 2018-05-15 2026-01-20 The Brigham And Women's Hospital, Inc. Compositions and methods related to tumor cell killers and vaccines
CA3109223A1 (en) * 2018-08-16 2020-02-20 Beyondspring Pharmaceuticals, Inc. Method and composition for stimulating immune response
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
EP4045076A1 (en) * 2019-10-15 2022-08-24 ModernaTX, Inc. Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease
TWI776276B (zh) * 2019-11-13 2022-09-01 中國醫藥大學 異種組織細胞組合物治療癌症之用途
AU2020395765A1 (en) 2019-12-03 2022-06-16 Neuvogen, Inc. Tumor cell vaccines
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001512009A (ja) * 1997-07-29 2001-08-21 ザ イミューン レスポンス コーポレイション 膜結合サイトカイン組成物およびこれを用いた免疫応答の調節方法
JP2002529707A (ja) * 1998-11-03 2002-09-10 セル ジェネシス インコーポレイテッド 癌関連抗原およびそれらの同定の方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5098702A (en) * 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
CA1339354C (en) * 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US6303121B1 (en) * 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
JP3051411B2 (ja) * 1989-03-14 2000-06-12 持田製薬株式会社 新規ｄｎａならびにそれを含有する発現プラスミド
US5266491A (en) * 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
US5436146A (en) * 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
DE69114299T3 (de) 1990-09-14 2005-09-15 The Johns Hopkins University Verfahren und zusammensetzungen für gentherapie und stärkung des immunsystems.
US5674486A (en) * 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US7211259B1 (en) * 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
WO1994026290A1 (en) * 1993-05-07 1994-11-24 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
US6506604B2 (en) * 1993-06-11 2003-01-14 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
ES2185770T3 (es) * 1995-04-08 2003-05-01 Lg Chemical Ltd Anticuerpo monoclonal especifico para 4-1bb humano y linea celular que lo produce.
US6093570A (en) * 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6040183A (en) * 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6033674A (en) * 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US6805869B2 (en) * 1996-06-12 2004-10-19 Shanghai Cp Guojian Pharmaceutical Co., Ltd. Cellular vaccines and immunotherapeutics and methods for their preparation
RU2192281C2 (ru) * 1996-10-11 2002-11-10 Бристол-Маерс Сквибб Компани Способы и композиции для иммуномодуляции
WO1998046728A1 (en) 1997-04-14 1998-10-22 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant aav product
US6037177A (en) * 1997-08-08 2000-03-14 Cell Genesys, Inc. Method for increasing the efficiency of recombinant AAV production
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999038954A1 (en) * 1998-02-02 1999-08-05 Johns Hopkins University School Of Medicine A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
CA2352783C (en) * 1998-12-03 2012-04-10 The Regents Of The University Of California Stimulation of t cells against self antigens using ctla-4 blocking agents
US20030035790A1 (en) * 1999-01-15 2003-02-20 Shu-Hsia Chen Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
AU5458500A (en) 1999-06-02 2000-12-18 Cell Genesys, Inc. Regulation of systemic immune responses utilizing cytokines and antigens
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
CN1168740C (zh) * 2001-04-04 2004-09-29 上海美恩生物技术有限公司 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
EP1440090A2 (en) * 2001-10-23 2004-07-28 Centre for Translational Research in Cancer A synthetic chimeric fusion protein with immuno-therapeutic uses
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US7176022B2 (en) * 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001512009A (ja) * 1997-07-29 2001-08-21 ザ イミューン レスポンス コーポレイション 膜結合サイトカイン組成物およびこれを用いた免疫応答の調節方法
JP2002529707A (ja) * 1998-11-03 2002-09-10 セル ジェネシス インコーポレイテッド 癌関連抗原およびそれらの同定の方法

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503039A (ja) * 2007-11-07 2011-01-27 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ 癌治療用医薬組成物
JP2013525450A (ja) * 2010-04-27 2013-06-20 ザ・ジョンズ・ホプキンス・ユニバーシティ 新生物（腫瘍）を治療するための免疫原性組成物及び方法。
JP2013529192A (ja) * 2010-04-27 2013-07-18 ザ・ジョンズ・ホプキンス・ユニバーシティ 新生物（腫瘍）を治療するための免疫原性組成物及び方法。
US9248170B2 (en) 2010-04-27 2016-02-02 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia
JP2014527983A (ja) * 2011-09-19 2014-10-23 ザ ジョンズ ホプキンス ユニバーシティー 癌免疫療法
JP2018021047A (ja) * 2011-09-19 2018-02-08 ザ ジョンズ ホプキンス ユニバーシティー 癌免疫療法
JP2015518901A (ja) * 2012-06-08 2015-07-06 アデュロ バイオテック 癌免疫療法のための組成物および方法
JP2015523412A (ja) * 2012-07-30 2015-08-13 ワウ ヒン イェウング，アレックス 腫瘍細胞、ＧＭ‐ＣＳＦのトランスジェニック発現を伴う腫瘍溶解性ウイルスベクター、および免疫チェックポイントモジュレーターなどの成分の少なくとも２種または全３種の同時投与により作られる生のｉｎｖｉｖｏ腫瘍特異的がんワクチンシステム
US11759509B2 (en) 2013-03-29 2023-09-19 Sumitomo Pharma Co., Ltd. WT1 antigen peptide conjugate vaccine
JP2019135251A (ja) * 2015-05-20 2019-08-15 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
US12090183B2 (en) 2016-03-10 2024-09-17 Cg Oncology, Inc. Methods of treating solid or lymphatic tumors by combination therapy
US12383608B2 (en) 2016-11-30 2025-08-12 Sumitomo Pharma Co., Ltd. WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides
US11596660B2 (en) 2017-04-14 2023-03-07 Cg Oncology, Inc. Methods of treating bladder cancer
US12370229B2 (en) 2017-04-14 2025-07-29 Cg Oncology, Inc. Methods of treating bladder cancer
JP2025531267A (ja) * 2022-09-16 2025-09-19 コリア ニュークリア エンジニアリング カンパニー リミテッド アブスコパル効果を有する、がんの予防または治療用組成物およびこれを用いたがんの予防または治療方法

Also Published As

Publication number Publication date
JP2014169299A (ja) 2014-09-18
EP2859901A1 (en) 2015-04-15
JP5607000B2 (ja) 2014-10-15
WO2004093831A2 (en) 2004-11-04
US20120034242A1 (en) 2012-02-09
EP1608321A4 (en) 2011-08-31
EP1608321A2 (en) 2005-12-28
JP2011252006A (ja) 2011-12-15
US20050002916A1 (en) 2005-01-06
US20040197312A1 (en) 2004-10-07
CA2519563A1 (en) 2004-11-04
WO2004093831A3 (en) 2006-04-06
EP2574346A1 (en) 2013-04-03

Similar Documents

Publication Publication Date Title
JP5607000B2 (ja) サイトカイン発現細胞ワクチンの組み合わせ
Keenan et al. Whole cell vaccines—past progress and future strategies
Baskar et al. Major histocompatibility complex class II+ B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.
EP2772262B1 (en) Cancer immunotherapy compositions and methods of use
US8287856B2 (en) PD-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
AU2016205215B2 (en) Methods and compositions for combination immunotherapy
Kozłowska et al. Therapeutic gene modified cell based cancer vaccines
JP2022553192A (ja) 癌ワクチン
US8425897B2 (en) Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use
US20070231298A1 (en) Cytokine-expressing cancer immunotherapy combinations
Naz et al. Prophylactic vaccines for prevention of prostate cancer
US20080267935A1 (en) AraC in combination with a cytokine-secreting cell and methods of use thereof
Sharma et al. Immunotherapy in Gynecological Malignancies
Murphy et al. Michele WL Teng, Maria Moeller, Phillip K. Darcy
Sas HER-2/neu-targeted immunoprevention of breast cancer
Chiriva-Internati et al. Clinical perspectives in cancer vaccines for hematological diseases
Mansoor et al. Genetically Modified T Cell Therapy Optimisation of the Chimeric T Cell Receptor for Cancer Therapy

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20070316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070323

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20070327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101026

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101223

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110811

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110825

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110831